



Receipt
#18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Herve Bazin and Dominique Latinne
Serial No. : 09/056,072 Art Unit: 1642
Filed : April 7, 1998 Examiner: Unassigned
For : LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Activation and Proliferation

Commissioner of Patents & Trademarks
Washington, D.C. 20231
Attn: Application Processing Division
Customer Correction Branch

REQUEST TO CORRECT FILING RECEIPT

SIR:

Applicants request that the filing receipt (a copy of which is attached) be corrected. Please correct the first name of the inventor Latinne to read: **"DOMINIQUE"**.

Please also add the priority information to read:

**"WHICH IS A CIP OF 08/407,009 03/29/95 ABN
WHICH IS A CIP OF 08/119,032 09/09/93 ABN
WHICH IS A CIP OF 08/027,008 03/05/93 ABN"**

Please issue a corrected filing receipt as requested above.

Also, enclosed is a self-addressed postage paid postcard.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, Attention: Application Processing Division, Customer Correction Branch

Raymond J. Lillie 5/26/98
Raymond J. Lillie, Esq. Date

Respectfully submitted,

Raymond J. Lillie
Raymond J. Lillie
Reg. No. 31,778

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068

P. 2-103X
(Rev. 8-95)

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

RJL

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/056,072	04/07/98	1642	\$790.00	61750221	53	14	3

CARELLA BYRNE BAIN GILFILLAN CECCHI,
STEWART & OLSTEIN
6 BECKER FRAM ROAD
ROSELAND NJ 07068

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

HERVE BAZIN, BRUSSELS, BELGIUM; ~~DOMINIQUE~~ LATINNE,
BRUSSELS, BELGIUM. *DOMINIQUE*

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A DIV OF 08/472,281 06/07/95 PAT 5,766,592
WHICH IS A CIP OF 03/407,009 03/29/95 ABN
WHICH IS A CIP OF 03/119,032 09/09/93 ABN
WHICH IS A CIP OF 03/027,008 03/05/93 ABN

TITLE

LO-CD2A ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION
AND PROLIFERATION

PRELIMINARY CLASS: 424

DATE RECEIVED:	<i>5-4-98</i>
DATES ENTERED:	
DOCKETED BY:	<i>pm</i>
DATE:	

MAY 1968
Received By
George Brown
Graham (Cecil) Stewart
& (Miss)

• • •

2

This license

Parts 500 +

Figure 1. The effect of the number of trials on the mean accuracy of the responses. Error bars represent standard error.

the application